Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Open access
Hall, Amy B., Newsome, Dave, Wang, Yuxin, Boucher, Diane M., Eustace, Brenda, Gu, Yong, Hare, Brian, Johnson, Mac A., Li, Howard, Milton, Sean, Murphy, Cheryl E., Takemoto, Darin, Tolman, Crystal, Wood, Mark, Charlton, Peter, Charrier, Jean-Damien, Furey, Brinley, Golec, Julian, Reaper, Philip M., Pollard, John R.·2014·Oncotarget

Abstract

// Amy B. Hall 1,* , Dave Newsome 1,* , Yuxin Wang 1,* , Diane M. Boucher 1 , Brenda Eustace 1 , Yong Gu 1 , Brian Hare 1 , Mac A. Johnson 1 , Howard Li 1 , Sean Milton 1 , Cheryl E. Murphy 1 , Darin Takemoto 1 , Crystal Tolman 1 , Mark Wood 1 , Peter Charlton 2 , Jean-Damien Charrier 2 , Brinley Furey 1 , Julian Golec 2 , Philip M. Reaper 2 and John R. Pollard 2 1 Vertex Pharmaceuticals Inc, Boston, MA, USA 2 Vertex Pharmaceuticals (Europe) Ltd, Milton Park, Abingdon, Oxfordshire, UK * These authors contributed equally to this work Correspondence: John R Pollard , email: // Keywords : ATR, DNA damage response, VX-970 Received : June 9, 2014 Accepted : July 2, 2014 Published : July 3, 2014 Abstract Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor. This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR). ATR kinase is a critical regulator of this pathway, and its inhibition has been shown to sensitize some cancer, but not normal, cells in vitro to DNA damaging agents. However, there are limited in vivo proof-of-concept data for ATR inhibition. To address this we profiled VX-970, the first clinical ATR inhibitor, in a series of in vitro and in vivo lung cancer models and compared it with an inhibitor of the downstream kinase Chk1. VX-970 markedly sensitized a large proportion of a lung cancer cell line and primary tumor panel in vitro to multiple DNA damaging drugs with clear differences to Chk1 inhibition observed. In vivo VX-970 blocked ATR activity in tumors and dramatically enhanced the efficacy of cisplatin across a panel of patient derived primary lung xenografts. The combination led to complete tumor growth inhibition in three cisplatin-insensitive models and durable tumor regression in a cisplatin-sensitive model. These data provide a strong rationale for the clinical evaluation of VX-970 in lung cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2158

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 199

Metadata

Authors
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., Murphy, C. E., Takemoto, D., Tolman, C., Wood, M., Charlton, P., Charrier, J.-D., Furey, B., Golec, J., Reaper, P. M., & Pollard, J. R.
Venue
Oncotarget
Published
2014-07-03
Volume
5
Issue
14
Pages
5674-5685
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2132089894
Cited by
199
References
10
FWCI
6.81
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. https://app.cochat.ai/papers/10.18632/oncotarget.2158
The paper
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., Murphy, C. E., Takemoto, D., Tolman, C., Wood, M., Charlton, P., Charrier, J.-D., Furey, B., Golec, J., Reaper, P. M., & Pollard, J. R. (2014). Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. https://doi.org/10.18632/oncotarget.2158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.